CFTR-Activating Compounds for Constipation and Dry Eye
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for constipation and dry eye disorders are inadequate, with existing laxatives and medications showing variable efficacy and limited options for moderate-to-severe cases, and there is a need for safe and effective therapeutic solutions.
Innovation Solution
Development of compounds that activate the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) to treat constipation, dry eye, cholestatic liver disease, and pulmonary diseases by increasing lacrimation and improving intestinal fluid secretion and motility.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing laxatives and chloride channel activators (lubiprostone, linaclotide) are used to treat constipation, then therapeutic options are available, but efficacy is variable and unimpressive
Solution Approach 1:
The patent applies parameter changes by developing new chemical compounds with modified molecular structures (Formula I with various substituents R1-R6) that target CFTR chloride channels. These structural modifications aim to optimize binding affinity and activation potency, thereby improving therapeutic efficacy and reliability compared to existing laxatives and chloride channel activators.
Solution Approach 2:
The patent employs composite materials by creating hybrid molecular structures that combine different functional groups (aromatic rings, heterocycles, substituent patterns) into a single pharmacophore. This composite approach allows for fine-tuning of pharmacological properties to achieve both high efficacy and broad adaptability across different patient populations with constipation.
2Object-affected harmful factors
If topical cyclosporine is used for dry eye, then anti-inflammatory effect is achieved, but it does not eliminate all symptoms in most dry eye patients
Solution Approach 1:
The patent applies the taking out principle by extracting the core therapeutic function (CFTR activation) from the existing anti-inflammatory mechanism of cyclosporine. The new compounds directly activate CFTR chloride channels to increase tear secretion, separating this secretory function from the anti-inflammatory action, thereby addressing both inflammation and symptom completeness more effectively.
Solution Approach 2:
The patent implements universality by designing compounds that simultaneously address multiple aspects of dry eye pathology: they activate CFTR to increase tear secretion while also providing anti-inflammatory effects. This multi-functional approach eliminates more symptoms compared to single-mechanism treatments like topical cyclosporine.
3Adaptability or versatility
If CFTR-activating compounds are developed to treat multiple conditions (constipation, dry eye, cholestatic liver disease, pulmonary diseases), then therapeutic versatility is improved, but drug development complexity increases
Solution Approach 1:
The patent applies universality by designing a single class of compounds (Formula I) that can treat multiple CFTR-related conditions including constipation, dry eye, cholestatic liver disease, and pulmonary diseases. The core pharmacophore structure remains consistent across all indications, providing therapeutic versatility without requiring separate drug development programs for each condition.
Solution Approach 2:
The patent uses segmentation by dividing the molecular structure into modular components (core heterocyclic ring, aromatic substituents, side chains with R1-R6 groups) that can be independently optimized. This modular approach allows systematic exploration of structure-activity relationships to achieve broad therapeutic coverage while managing development complexity through structured molecular design.
Data Source
Figure 1
Figure 2A
Figure 2B~2D
AI summary
Provided herein are compounds that activate CFTR and methods for treating constipation, dry eye disorders or other diseases and disorders.